Trump receives remdesivir, an emerging treatment for Covid-19 symptoms

White House physician Dr. Sean Conley said Trump “is doing very well.”

President Donald Trump, who was hospitalized at Walter Reed Military Medical Center on Friday following a positive coronavirus test, has begun receiving the drug remdesivir, which doctors have used to treat some cases of Covid-19.

White House physician Dr. Sean Conley has said the president has symptoms that include a low-grade fever, cough, congestion, and fatigue. He issued a memo late Friday saying that Trump “is doing very well.” “He is not requiring any supplemental oxygen, but in consultation with specialists we have elected to initiate remdesivir therapy. He has completed his first dose and is resting comfortably.”

Remdesivir is allowed for treatment under an emergency use authorization (EUA), which the Food and Drug Administration (FDA) grants for treatment of illnesses “when there are no adequate, approved, and available alternatives.”

It is not yet clear how severe Trump’s case is; though remdesivir is typically used for moderate to severe cases, it is possible Trump’s doctors are erring on the side of aggressively treating given his responsibilities as the leader of the United States.

Trump announced his diagnosis early Friday morning, and, not long after, received an initial does of the experimental polyclonal antibody treatment. As Vox’s Umair Irfan has explained, the experimental treatment is currently undergoing testing in clinical trials conducted by Regeneron, a biotech company, but does not have authorization from the FDA.

Trump was authorized to use the polyclonal cocktail under compassionate use by doctors. Regeneron has said its research so far has found the treatment, known as REGN-COV2, to reduce symptoms and the presence of the virus in those with Covid-19. Regeneron’s research has yet to be peer reviewed, Irfan notes, so it is difficult to know how well REGN-COV2 actually works.

For now, the president’s only had a single dose of the experimental treatment before beginning the more routine treatment of remdesivir. Conley said Trump is also taking some vitamins and supplements, including Vitamin D, which White House coronavirus task force member Dr. Anthony Fauci has recommended taking in order to reduce “susceptibility to infection.”

What we know about remdesivir and its effectiveness

It’s difficult to draw conclusions about how the president is doing based on his course of treatment. Gilead, the pharmaceutical company that makes remdesivir, has recommended it for patients with moderate to severe cases of Covid-19, regardless of the need for supplemental oxygen.

When the FDA issued an emergency authorization of the drug back on May 1, it did so for patients with severe cases of Covid-19 — meaning those with low blood oxygen levels, who receive supplemental oxygen or are on a ventilator.

In August, the FDA said that the drug did not need to be limited to only the most severe cases, and on Thursday, the FDA renewed the emergency authorization of the drug.

The drug is still pending formal FDA approval.

Having been used for Covid-19 patients for five months, there have been several studies of the drug’s effectiveness, which is assessed by how quickly a patient shows improvement while on the drug compared to receiving a placebo.

It appears to be effective for severe cases, but makes little difference in moderate cases.

When it received its first emergency authorization in May, a trial at the time showed that severe patients recovered in 11 days in the course of its use, compared to 15 days for patients on a placebo.

Another study showed that the average time to improvement was five days among those with mild and moderate cases of the disease, according to a clinical trial, with no difference between those administered remdesivir and those receiving the placebo.

A third study found patients with moderate cases are 65 percent more likely to show improvement than when using a placebo when the treatment lasts for five days. That difference is erased when the treatment lasts for 10 days.

According to the health news website STAT, medical researchers have not been given access to Gilead’s raw research data to verify these clinical trials.

In an independent study published Saturday in the peer-reviewed medical journal The Lancet, the authors did not find a significant difference between patients with severe infections who used remdesivir and those on a placebo. The authors called these findings “disappointing,” and said it did not appear to lower viral load or mortality.

The drug’s side effects are still being investigated as well. Gilead notes that “serious and unexpected side effects may happen,” including allergic reactions and changes to patients’ live chemistry. The European Union is looking into whether the drug can cause kidney damage in some patients. Overall, Gilead has warned that remdesivir “is still being studied so it is possible that all of the risks are not known at this time.”

This therapy is not cheap. Private insurance will be billed $520 per vial, according to Gilead, and $390 per dose for those on some government health programs. For a five-day course of treatment, with a double dose on the first day, private insurers – as well as Medicare and Medicaid – will be charged $3,120. Government insurers, such as the Indian Health Services and the Department of Veterans Affairs, will be charged $2,340 per patient.

How much of those costs are passed on to the patient depends on their insurance plan.

A drug price watchdog group, Public Citizen, estimated that the drugmaker received $70 million in taxpayer dollars to develop the treatment, and called the subsequent pricing an “offensive display of hubris and disregard for the public.”

Gilead’s CEO has said this price is “well below the value” of the drug.

In July, the Trump administration worked out an agreement with Gilead that allowed the company to supply half a million treatment courses to US hospitals through September. And in October, the FDA said medical professionals could begin buying the therapeutic directly from Gilead. President Trump championed the drug’s use before needing, on Friday, to use it himself.

Help keep Vox free for all

Millions turn to Vox each month to understand what’s happening in the news, from the coronavirus crisis to a racial reckoning to what is, quite possibly, the most consequential presidential election of our lifetimes. Our mission has never been more vital than it is in this moment: to empower you through understanding. But our distinctive brand of explanatory journalism takes resources. Even when the economy and the news advertising market recovers, your support will be a critical part of sustaining our resource-intensive work. If you have already contributed, thank you. If you haven’t, please consider helping everyone make sense of an increasingly chaotic world: Contribute today from as little as $3.